The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy
Colorectal Cancer
DRUG: Tas-102(Suyuan) combined with bevacizumab
Progression Free Survival, The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse, 2 years
Overall Survival, Time from randomization to death from any cause, 3 year|Objective Response Rate, It refers to the proportion of patients (mainly solid tumors) whose tumor has shrunk to a certain extent and remained there for a certain period of time, including Complete Response (CR) and Partial Response (PR), 2 year|Quality of life score, Quantitative scoring system for patients' self-subjective self-assessment of current symptom tolerance, 3 year
To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy